The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression†
Open accessAbstract
UNLABELLED: Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate stage-specific fibrosis progression rates and their determinants in these individuals. A systematic review of published prognostic studies was undertaken. Study inclusion criteria were as follows: (1) presence of HCV infection determined by serological assays; (2) available information about age at assessment of liver disease or HCV acquisition; (3) duration of HCV infection; and (4) histological and/or clinical diagnosis of cirrhosis. Annual stage-specific transition probabilities (F0-->F1, ... , F3-->F4) were derived using the Markov maximum likelihood estimation method and a meta-analysis was performed. The impact of potential covariates was evaluated using meta-regression. A total of 111 studies of individuals with chronic HCV infection (n = 33,121) were included. Based on the random effects model, the estimated annual mean (95% confidence interval) stage-specific transition probabilities were: F0-->F1 0.117 (0.104-0.130); F1-->F2 0.085 (0.075-0.096); F2-->F3 0.120 (0.109-0.133); and F3-->F4 0.116 (0.104-0.129). The estimated prevalence of cirrhosis at 20 years after the infection was 16% (14%-19%) for all studies, 18% (15%-21%) for cross-sectional/retrospective studies, 7% (4%-14%) for retrospective-prospective studies, 18% (16%-21%) for studies conducted in clinical settings, and 7% (4%-12%) for studies conducted in nonclinical settings. Duration of infection was the most consistent factor significantly associated with progression of fibrosis. CONCLUSION: Our large systematic review provides increased precision in estimating fibrosis progression in chronic HCV infection and supports nonlinear disease progression. Estimates of progression to cirrhosis from studies conducted in clinical settings were lower than previous estimates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
How should meta‐regression analyses be undertaken and interpreted?
Thompson, S. G., & Higgins, J. P. T. (2002) · Statistics in Medicine · doi:10.1002/sim.1187 · Cited by 3,026
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M., Hoofnagle, J. H., Manns, M., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,593
Advanced methods in meta‐analysis: multivariate approach and meta‐regression
van Houwelingen, H. C., Arends, L. R., & Stijnen, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1040 · Cited by 1,580
Classification of chronic viral hepatitis: a need for reassessment
Scheuer, P. J. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90084-o · Cited by 1,576
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
Cited by
Natural history of hepatitis C.
Westbrook, R. H., & Dusheiko, G. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.012 · Cited by 1,049
Epidemiology and natural history of HCV infection
Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.107 · Cited by 994
Self-citationConti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., Foschi, F. G., Lenzi, M., Mazzella, G., Verucchi, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.015 · Cited by 897
Davis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Friedrich-Rust, M., Wunder, K., Kriener, S., Sotoudeh, F., Richter, S., Bojunga, J., Herrmann, E., Poynard, T., Dietrich, C. F., Vermehren, J., et al. (2009) · Radiology · doi:10.1148/radiol.2523081928 · Cited by 620
Rosen, H. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1006613 · Cited by 487
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
Razavi, H., ElKhoury, A. C., Elbasha, E., Estes, C., Pasini, K., Poynard, T., & Kumar, R. (2013) · Hepatology · doi:10.1002/hep.26218 · Cited by 474
Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12248 · Cited by 477
Self-citationWebster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
Viral hepatitis and liver cancer
Ringehan, M., McKeating, J. A., & Protzer, U. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0274 · Cited by 410
Spearman, C. W., Dusheiko, G. M., Hellard, M., & Sonderup, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32320-7 · Cited by 404
Historical review of the causes of cancer
Blackadar, C. B. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.54 · Cited by 389
Global epidemiology and burden of HCV infection and HCV-related disease
Thrift, A. P., El-Serag, H. B., & Kanwal, F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.176 · Cited by 382
Chhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
Simmons, B., Saleem, J., Hill, A., Riley, R. D., & Cooke, G. S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ948 · Cited by 314
Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J.-P., Lester, L., Sievert, W., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61795-5 · Cited by 299
Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies†
Popov, Y., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 296
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
Bochud, P.-Y., Cai, T., Overbeck, K., Bochud, M., Dufour, J.-F., Müllhaupt, B., Borovicka, J., Heim, M., Moradpour, D., Cerny, A., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.016 · Cited by 287
Kandeel, A., Genedy, M., El‐Refai, S., Funk, A. L., Fontanet, A., & Talaat, M. (2017) · Liver International · doi:10.1111/liv.13186 · Cited by 283
Chemopreventive strategies in hepatocellular carcinoma
Singh, S., Singh, P. P., Roberts, L. R., & Sanchez, W. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.143 · Cited by 273
Heffernan, A., Cooke, G. S., Nayagam, S., Thursz, M., & Hallett, T. B. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32277-3 · Cited by 265
Singh, S., Muir, A. J., Dieterich, D. T., & Falck-Ytter, Y. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.016 · Cited by 263
Simmons, B., Saleem, J., Heath, K., Cooke, G. S., & Hill, A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ396 · Cited by 261
Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma
D'souza, S., Lau, K. C., Coffin, C. S., & Patel, T. R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i38.5759 · Cited by 257
Natural history of acute and chronic hepatitis C
Maasoumy, B., & Wedemeyer, H. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.09.009 · Cited by 257
Natural History of Hepatitis C
Lingala, S., & Ghany, M. G. (2015) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2015.07.003 · Cited by 252
Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1313 · Cited by 101
Smith, D. J., Combellick, J., Jordan, A. E., & Hagan, H. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.07.004 · Cited by 104
Sex differences in chronic liver disease and benign liver lesions
Cooper, K. M., Delk, M., Devuni, D., & Sarkar, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100870 · Cited by 38
Linas, B. P., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., Freedberg, K. A., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw266 · Cited by 19
Metadata
- Authors
- Thein, H., Yi, Q., Dore, G. J., & Krahn, M. D.
- Venue
- Hepatology
- Published
- 2008-08
- Volume
- 48
- Issue
- 2
- Pages
- 418-431
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1984413237
- Cited by
- 829
- References
- 61
- FWCI
- 18.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.